Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Anti-viral drug improves hepatitis C treatment

  • Comment

Adding a direct acting anti-viral drug to the standard treatment regime for hepatitis C (peginterferon plus ribavirin) significantly increases the cure rate in the most difficult to treat patients, according to US research published online in The Lancet.

The study found adding the experimental protease inhibitor boceprevir nearly doubled the standard regimen’s effectiveness when it was given to people with genotype 1 hepatitis C for 48 weeks.

The two year trial was conducted at 67 sites involving 520 patients in the US, Canada and Europe.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs